NCT05582772 (TOPCOP3) is a NA clinical trial of GA+M Intervention in Metastatic Prostate Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT05582772?

NCT05582772 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT05582772?

Interventions in NCT05582772: GA+M Intervention, RSM intervention, GA+RSM intervention.

What condition does NCT05582772 study?

NCT05582772 studies Metastatic Prostate Cancer.

Is NCT05582772 still recruiting?

NCT05582772 is currently recruiting now. Last updated 3 July 2025.

Last reviewed 2025-07-03 · How we verify

NCT05582772: TOPCOP3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

Recruiting now NA Last updated 3 July 2025

What this trial tests

NA trial testing GA+M Intervention in Metastatic Prostate Cancer in 168 participants. Currently enrolling.

Timeline

23 May 2023

Primary endpoint
28 February 2027

28 February 2027

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	supportive care
Enrollment	168
Start date	23 May 2023
Primary completion	28 February 2027
Estimated completion	28 February 2027
Sites	3 locations across Canada

Drugs / interventions tested

GA+M Intervention
RSM intervention
GA+RSM intervention

Conditions studied

Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

University Health Network, Toronto

Who can join

65 and older, male only, with Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TOPCOP3 is a pilot factorial RCT of geriatric assessment and management, remote symptom monitoring, both interventions or neither, accompanied by an embedded process evaluation. This design is widely used to guide the evaluation of complex interventions and provides important data to aid design of larger RCTs. The trial itself falls within pilot trial goals including obtaining variance estimates for outcomes, assessment of recruitment potential, and understanding implementation issues vital to designing a larger trial. The investigators have clear feasibility objectives and an analytic plan as well as criteria to determine success and strong support from cancer advocacy and policy groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation.
Alibhai SMH, Puts M, Jin R, Godhwani K, et al · · 2024 · cited 2× · PMID 38521641 · DOI 10.1016/j.jgo.2024.101750

Verify or expand the search:

Other recruiting trials for Metastatic Prostate Cancer

Currently open trials in the same condition.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
NCT07290270 — Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07209176 — Physician- and Patient-based Barriers to NGS Testing · NA · recruiting
NCT07181161 — Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer · Phase 1, PHASE2 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05582772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 3 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05582772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing